DDInter1652 DDInter1680
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain.
Smallpox (Vaccinia) Vaccine, Live {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Smallpox (Vaccinia) Vaccine, Live {u} may lead to a major life threatening interaction when taken with {v} Risankizumab
Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Cladribine
Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Risankizumab